CATBライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (9 9月 2021 @ 13:00):

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States...

Stats
本日の出来高	98 872.00
平均出来高	528 916
時価総額	234.86M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.105 (1.23%)

Insider Trading

Date	Person	Action	Amount	type
2021-06-08	Harshbarger Benjamin	Buy	200 000	Stock Option (right to buy)
2021-06-02	Callori Fred	Buy	85 000	Stock Option (right to buy)
2021-06-02	Violin Jonathan	Buy	85 000	Stock Option (right to buy)
2021-06-02	Clauser Noah	Buy	600 000	Stock Option (right to buy)
2021-06-02	Kishbauch Michael D	Buy	100 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 86 transactions
Buy: 7 288 895 \| Sell: 328 827

ボリューム相関

長: -0.05 (neutral)

短: 0.18 (neutral)

Signal:(67.933) Neutral

Catabasis Pharmaceuticals 相関

10 最も正の相関
VNET	0.911
TTOO	0.908
LSXMA	0.905
TTGT	0.904
EGAN	0.904
RUBY	0.903
LSXMK	0.903
AVIR	0.902
ACRS	0.901
PTEN	0.901

10 最も負の相関
PAE	-0.908
SCR	-0.902
EBSB	-0.898
TYHT	-0.894
RAM	-0.89
SGEN	-0.88
BCTG	-0.88
ZGNX	-0.879
CPTA	-0.878
MOSY	-0.877

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Catabasis Pharmaceuticals 相関 - 通貨/商品

0.40
( neutral )

0.75
( moderate )

-0.07
( neutral )

0.53
( weak )

-0.23
( neutral )

-0.30
( neutral )

Financial Reports:

No articles found.

Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.